Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tian En Fu + cisplatin
- Development stage
- Unknown
- Lead developer
- Shanghai Wellcares Biopharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intracavitary
01
Overview
Tian En Fu (rmhTNF-NC) is a recombinant modified human tumor necrosis factor-alpha (TNF-alpha) developed by Shanghai Wellcares Biopharmaceutical. It is a Class 1 biological drug in China, engineered to have significantly higher anti-tumor activity and lower systemic toxicity compared to natural TNF. For the treatment of malignant pleural and peritoneal effusions, it is administered via intracavitary infusion in combination with cisplatin. The mechanism involves TNF-mediated direct cytotoxicity against tumor cells and vascular effects that reduce fluid accumulation, complemented by the DNA-damaging effects of cisplatin. While already approved in China for advanced non-small cell lung cancer (NSCLC) and non-Hodgkin's lymphoma, the combination with cisplatin for malignant effusions is currently under regulatory review following an NDA filing.
- Brand names
- Tian En Fu天恩福
- Other names
- Recombinant Modified Human TNF for Injection注射用重组改构人肿瘤坏死因子modified human TNF-alpha
02
Targets
DNATNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on Tian En Fu + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tian En Fu + cisplatin.